Gabreiel Ilerioluwa Oke - Department of Medical Laboratory Science, Ladoke Akintola University of Technology, Ogbomoso, Nigeria
Precious Fadele - Department of Medicine, University of Nigeria, Nsukka, Nigeria
Yusuff Adebayo Adebisi - Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria
Melody Okereke - Faculty of Pharmaceutical Sciences, University of Ilorin, Ilorin, Nigeria

HIV remains a global problem due to the lack of a therapy that can completely wipe out the virus from the body system of infected individuals (۱). Antiretroviral regimens (ARVs) have helped greatly in the fight against HIV as a lot of deaths have been prevented (۱). Antiretroviral regimens have helped in reducing viral replication of HIV and also to increase the life expectancy of individuals infected with HIV (۱). Although antiretroviral regimens have been highly effective, the viral reservoir cannot be cleared by antiretroviral regimens, and therefore, lifelong use of antiretroviral regimens is the only option for people living with HIV (۲). Meanwhile, broadly neutralizing antibodies (BNAbs) are being evaluated for their potential as long-acting alternatives to the use of antiretroviral regimens in HIV prevention and therapy (۳). BNAbs may be able to protect against HIV-infection and this may help to prevent people who are not living with HIV from being infected with the virus in the future (۱). Also, the use of BNAbs as a treatment has shown potential in clinical studies (۲) and it has also been reported that BNAbs may have prospects in the clearance of viral reservoir by interacting with the surface receptors of infected cells using the FC Domain of the antibody (۱). Furthermore, it has been reported that the main target for neutralizing antibodiesmaybe the BNAbsCD۴receptor on the T-cells (۴).

BNAbs, Human Immunodeficiency Virus, Antiretroviral Regimen, Antiretroviral Therapy, Acquired Immunodeficiency Syndrome